Westover Capital Advisors LLC Grows Stake in Exelixis, Inc. $EXEL

Westover Capital Advisors LLC raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 61.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 77,035 shares of the biotechnology company’s stock after purchasing an additional 29,316 shares during the period. Westover Capital Advisors LLC’s holdings in Exelixis were worth $3,182,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of EXEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Exelixis by 81.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock valued at $1,592,000 after buying an additional 19,407 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Exelixis by 4.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after acquiring an additional 68,133 shares during the period. Focus Partners Wealth raised its stake in shares of Exelixis by 83.4% in the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock valued at $1,420,000 after acquiring an additional 17,483 shares during the period. Geneos Wealth Management Inc. lifted its holdings in shares of Exelixis by 134.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 944 shares during the last quarter. Finally, Sivia Capital Partners LLC boosted its stake in shares of Exelixis by 23.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock worth $633,000 after purchasing an additional 2,764 shares during the period. 85.27% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. UBS Group set a $41.00 price objective on shares of Exelixis in a research report on Monday, January 5th. Weiss Ratings reiterated a “buy (b)” rating on shares of Exelixis in a report on Thursday, January 22nd. Truist Financial set a $51.00 price target on Exelixis in a research note on Wednesday, January 14th. Citigroup downgraded Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. Finally, Zacks Research upgraded Exelixis from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $47.11.

Insider Activity at Exelixis

In other news, EVP Patrick J. Haley sold 28,043 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $42.58, for a total value of $1,194,070.94. Following the completion of the sale, the executive vice president owned 374,029 shares of the company’s stock, valued at approximately $15,926,154.82. This represents a 6.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 72,230 shares of company stock valued at $3,046,923. Insiders own 2.82% of the company’s stock.

Exelixis Trading Down 0.1%

EXEL opened at $42.94 on Thursday. The company has a market capitalization of $11.51 billion, a price-to-earnings ratio of 15.50, a PEG ratio of 0.73 and a beta of 0.42. Exelixis, Inc. has a 12-month low of $32.38 and a 12-month high of $49.62. The business’s fifty day simple moving average is $43.67 and its 200-day simple moving average is $40.94.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.20. Exelixis had a return on equity of 36.52% and a net margin of 33.73%.The firm had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. During the same period in the previous year, the company posted $0.55 earnings per share. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. On average, equities research analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.